Michael C Donohue

List of Publications by Year
in descending order

80 papers	**9,462** citations	87888 **38** h-index	64796 **79** g-index
94 all docs	**94** docs citations	**94** times ranked	**10726** citing authors

#	Article	IF	Citations
1	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology, The, 2013, 12, 207-216.	10.2	3,378
2	The A4 Study: Stopping AD Before Symptoms Begin?. Science Translational Medicine, 2014, 6, 228fs13.	12.4	588
3	The Preclinical Alzheimer Cognitive Composite. JAMA Neurology, 2014, 71, 961.	9.0	548
4	Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans. Alzheimer's and Dementia, 2010, 6, 239-246.	0.8	402
5	The Association Between Lower Extremity Continuous Peripheral Nerve Blocks and Patient Falls After Knee and Hip Arthroplasty. Anesthesia and Analgesia, 2010, 111, 1552-1554.	2.2	331
6	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA - Journal of the American Medical Association, 2017, 317, 2305.	7.4	311
7	Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. Brain, 2015, 138, 772-783.	7.6	200
8	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurology, 2020, 77, 735.	9.0	182
9	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 2015, 11, 865-884.	0.8	181
10	Sex, amyloid, and *APOE* ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well‐characterized cohorts. Alzheimer's and Dementia, 2018, 14, 1193-1203.	0.8	169
11	Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain, 2014, 137, 1550-1561.	7.6	150
12	Estimating long‐term multivariate progression from short‐term data. Alzheimer's and Dementia, 2014, 10, S400-10.	0.8	148
13	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	9.0	146
14	Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia. JAMA Neurology, 2015, 72, 446.	9.0	142
15	Continuous Femoral Nerve Blocks. Anesthesiology, 2011, 115, 774-781.	2.5	139
16	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimer's and Dementia, 2017, 13, 1004-1012.	0.8	139
17	Using social and mobile tools for weight loss in overweight and obese young adults (Project SMART): a 2 year, parallel-group, randomised, controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 747-755.	11.4	132
18	The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimer's and Dementia, 2010, 6, 257-264.	0.8	102

#	Article	IF	Citations
19	Continuous Peripheral Nerve Blocks. Anesthesiology, 2010, 112, 347-354.	2.5	100
20	Parental Ability to Discriminate the Weight Status of Children: Results of a Survey. Pediatrics, 2007, 120, e112-e119.	2.1	99
21	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Annals of Clinical and Translational Neurology, 2014, 1, 534-543.	3.7	96
22	Design and implementation of a randomized controlled social and mobile weight loss trial for young adults (project SMART). Contemporary Clinical Trials, 2014, 37, 10-18.	1.8	91
23	Continuous Femoral Nerve Blocks. Anesthesiology, 2012, 116, 665-672.	2.5	86
24	Predicting diagnosis and cognition with [18]F‑AV‑1451 tau PET and structural MRI in Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 570-580.	0.8	84
25	Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimer's and Dementia, 2018, 14, 1077-1087.	0.8	83
26	Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. Alzheimer's and Dementia, 2015, 11, 734-739.	0.8	80
27	Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention. Brain Communications, 2020, 2, fcaa007.	3.3	69
28	The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Frontiers in Behavioral Neuroscience, 2015, 9, 239.	2.0	66
29	The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. Alzheimer's and Dementia, 2015, 11, 823-831.	0.8	60
30	Infection Rates of Electrical Leads Used for Percutaneous Neurostimulation of the Peripheral Nervous System. Pain Practice, 2017, 17, 753-762.	1.9	58
31	Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease. JAMA Neurology, 2021, 78, 293.	9.0	57
32	Clinical trial management of participant recruitment, enrollment, engagement, and retention in the SMART study using a Marketing and Information Technology (MARKIT) model. Contemporary Clinical Trials, 2015, 42, 185-195.	1.8	56
33	Emerging β-Amyloid Pathology and Accelerated Cortical Atrophy. JAMA Neurology, 2014, 71, 725.	9.0	51
34	Students at Risk for Being Reported for Cheating. Journal of Academic Ethics, 2015, 13, 217-228.	2.2	45
35	The A4 study: β‑amyloid and cognition in 4432 cognitively unimpaired adults. Annals of Clinical and Translational Neurology, 2020, 7, 776-785.	3.7	43
36	Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurology, 2015, 72, 554.	9.0	42

#	Article	IF	Citations
37	Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. Neurology, 2016, 86, 1887-1896.	1.1	42
38	Bayesian latent time joint mixed effect models for multicohort longitudinal data. Statistical Methods in Medical Research, 2019, 28, 835-845.	1.5	41
39	Predicting the course of Alzheimer's progression. Brain Informatics, 2019, 6, 6.	3.0	40
40	Pediatricians' weight assessment and obesity management practices. BMC Pediatrics, 2009, 9, 19.	1.7	39
41	The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimer's and Dementia, 2015, 11, 1171-1179.	0.8	37
42	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2015, 2, 534-547.	3.7	32
43	Impact of CRFR1 Ablation on Amyloid-β Production and Accumulation in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 1175-1184.	2.6	32
44	Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment. Neurobiology of Aging, 2016, 48, 172-181.	3.1	28
45	Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 657-668.	2.4	27
46	Continuous Femoral Nerve Blocks. Anesthesia and Analgesia, 2012, 115, 721-727.	2.2	26
47	The relative efficiency of time-to-threshold and rate of change in longitudinal data. Contemporary Clinical Trials, 2011, 32, 685-693.	1.8	25
48	The Computerized Cognitive Composite (C3) in A4, an Alzheimer's Disease Secondary Prevention Trial. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-9.	2.7	25
49	PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALS. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-6.	2.7	23
50	Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimer's and Dementia, 2015, 11, 1069-1079.	0.8	22
51	Time between milestone events in the Alzheimer's disease amyloid cascade. NeuroImage, 2021, 227, 117676.	4.2	20
52	Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials. Journal of Nutrition, Health and Aging, 2012, 16, 360-364.	3.3	19
53	Continuous Transversus Abdominis Plane Nerve Blocks: Does Varying Local Anesthetic Delivery Method—Automatic Repeated Bolus Versus Continuous Basal Infusion—Influence the Extent of Sensation to Cold?: A Randomized, Triple-Masked, Crossover Study in Volunteers. Anesthesia and Analgesia, 2017, 124, 1298-1303.	2.2	19
54	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. GeroScience, 2022, 44, 1807-1823.	4.6	19

#	Article	IF	Citations
55	Cross‑validation of optimized composites for preclinical Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 123-129.	3.7	18
56	Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. Neurodegenerative Diseases, 2018, 18, 173-190.	1.4	18
57	Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). Journal of Alzheimer's Disease, 2019, 70, 131-138.	2.6	18
58	Applications of Neuroimaging to Disease-Modification Trials in Alzheimer's Disease. Behavioural Neurology, 2009, 21, 129-136.	2.1	17
59	A randomized, triple-masked, active-controlled investigation of the relative effects of dose, concentration, and infusion rate for continuous popliteal-sciatic nerve blocks in volunteers. British Journal of Anaesthesia, 2015, 114, 121-129.	3.4	17
60	THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER'S DISEASE (TRC-PAD) PROJECT: AN OVERVIEW. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-5.	2.7	17
61	Pilot Study to Show the Feasibility of a Multicenter Trial of Home-based Assessment of People Over 75 Years Old. Alzheimer Disease and Associated Disorders, 2010, 24, 256-263.	1.3	16
62	Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. NeuroImage, 2019, 186, 446-454.	4.2	16
63	F3‑04‑01: The A4 trial: Anti‑amyloid treatment of asymptomatic Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, P425.	0.8	15
64	Developing Dementia Prevention Trials. Alzheimer Disease and Associated Disorders, 2013, 27, 356-362.	1.3	15
65	Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12118.	2.4	12
66	The relative efficiency of time‑to‑progression and continuous measures of cognition in presymptomatic Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 308-318.	3.7	11
67	Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial‑Ready Cohort study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12135.	3.7	11
68	Participant satisfaction with dementia prevention research: Results from Home‑Based Assessment trial. Alzheimer's and Dementia, 2018, 14, 1397-1405.	0.8	10
69	Serratus anterior plane versus paravertebral nerve blocks for postoperative analgesia after non-mastectomy breast surgery: a randomized controlled non-inferiority trial. Regional Anesthesia and Pain Medicine, 2021, 46, 773-778.	2.3	8
70	Requiring an amyloid‑β_{1-42} biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimer's and Dementia, 2011, 7, 245-246.	0.8	5
71	A randomized clinical trial to evaluate home‑based assessment of people over 75 years old. Alzheimer's and Dementia, 2019, 15, 615-624.	0.8	5
72	Continuous Popliteal-Sciatic Blocks for Postoperative Analgesia: Traditional Proximal Catheter Insertion Superficial to the Paraneural Sheath Versus a New Distal Insertion Site Deep to the Paraneural Sheath. Anesthesia and Analgesia, 2019, 128, e104-e108.	2.2	4

#	Article	IF	Citations
73	Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach. Alzheimer's and Dementia, 2020, 16, 797-803.	0.8	4
74	Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial. journal of prevention of Alzheimer's disease, The, 2022, 9, 255-261.	2.7	4
75	Basal Infusion<i>versus</i>Automated Boluses and a Delayed Start Timer for "Continuous" Sciatic Nerve Blocks after Ambulatory Foot and Ankle Surgery: A Randomized Clinical Trial. Anesthesiology, 2022, 136, 970-982.	2.5	3
76	O3-03-01: Update on hypothetical model of Alzheimer's disease biomarkers. , 2013, 9, P521-P522.		2
77	Disease progression models for dominantly-inherited Alzheimer's disease. Brain, 2018, 141, 1244-1246.	7.6	2
78	Asynergistic Regression Based on Maximized Rank Correlation. Communications in Statistics Part B: Simulation and Computation, 2007, 37, 92-105.	1.2	0
79	Statistics and Clinical Data Analysis: A Reference Guide. , 2011, , 651-672.		0
80	Proportional Hazards Mixed-Effects Models and Applications. Chapman & Hall/CRC Biostatistics Series, 2007, , 297-322.	0.0	0